Cancer hurts millions of people every year. It is hard to treat because the disease is very complicated. A new study, released on March 17 in the open‑access journal PLOS Biology, suggests a fresh idea. Researchers from Shandong University in China changed a friendly gut bacterium, Escherichia coli Nissle 1917 (EcN), so it can carry cancer‑killing medicine and find tumors in mice.
Our bodies already host many bacteria that can help or harm us. Scientists are now asking if they can re‑program these microbes to fight cancer. The answer is still being tested.
In the lab, the team gave EcN the instructions to make Romidepsin (also called FK228), a drug approved by the FDA for cancer treatment. By editing the bacterium’s genes, they created a version that can produce the medicine on its own. They then gave mice breast‑cancer cells and treated them with the engineered bacteria.
Tumor Targeting and Drug Release
The results showed that EcN moved into the tumor and released Romidepsin right where it was needed. This happened both in test‑tube experiments and in living mice, proving the bacteria could act like a tiny delivery truck that drops the drug inside the cancer.
More work is still required. The method has never been tried in people, and future tests must check for possible side effects and ways to safely clear the bacteria after treatment. These issues will decide how useful engineered EcN can become for cancer patients.
Two‑Way Cancer Attack
EcN shows big potential as a tumor‑seeking bacterium. By using the engineered version, scientists can build a therapy that both makes a small‑molecule cancer drug and brings it straight to the tumor. The mouse study gives a strong start for designing bacteria that can produce anticancer medicines and help target tumors, opening new doors for future research.
The combination of EcN’s ability to live inside tumors and Romidepsin’s cancer‑killing power creates a dual‑action treatment that could change how we fight the disease.